更新于：2024-12-06
Candesartan Cilexetil
坎地沙坦酯
更新于：2024-12-06
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 英国 (1997-04-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C33H34N6O6 |
InChIKeyGHOSNRCGJFBJIB-UHFFFAOYSA-N |
CAS号145040-37-5 |
关联
198
项与 坎地沙坦酯 相关的临床试验Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury
坎地沙坦酯片在健康受试者中餐后状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
坎地沙坦酯片在健康受试者中空腹状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验
100 项与 坎地沙坦酯 相关的临床结果
登录后查看更多信息
100 项与 坎地沙坦酯 相关的转化医学
登录后查看更多信息
100 项与 坎地沙坦酯 相关的专利（医药）
登录后查看更多信息
3,259
项与 坎地沙坦酯 相关的文献（医药）2024-12-31Clinical and experimental hypertension (New York, N.Y. : 1993)
Chronic exercise improves renal AT
1
and ETB receptor functions via modulating GRK4 expression in obese Zucker rats
Article
作者: Li, Zhengsheng ; Lu, Jingjing ; Yang, Yinan ; Wei, Fangning
BACKGROUND:
Physical activity has profound benefits on health, especially in patients with cardiovascular and metabolic disease. Exercise training can reduce oxidative stress, improve renal function, and thus lower blood pressure. However, the effect of exercise training on angiotensin II type 1 receptors (AT1R) and endothelin subtype B receptors (ETBR)-mediated diuresis and natriuresis in obese Zucker rats is unclear.
METHODS:
Lean and obese Zucker rats were exercised or placed on a nonmoving treadmill for 8 weeks. Blood pressure was measured by tail-cuff plethysmography, and functions of AT1R and ETBR in the kidney were measured by natriuresis, respectively.
RESULTS:
Our data showed that exercise training improved glucose and lipid metabolism, renal function and sodium excretion in obese Zucker rats, accompanied by decreased oxidative stress and GRK4 expression in obese Zucker rats. Moreover, exercise training reduced the Candesartan-induced an increase in diuresis and natriuresis and increased ETBR agonists (BQ3020)-mediated diuresis and natriuresis in obese Zucker rats, which were associated with decreased renal AT1R expression and ETBR phosphorylation levels.
CONCLUSIONS:
The results demonstrate that exercise training lowers blood pressure via improving renal AT1R and ETBR function through modulating GRK4 expression in Obese Zucker Rats and provides potentially effective targets for obesity-related hypertension.
2024-12-31BLOOD PRESSURE
Guidelines-based therapeutic strategies for controlling hypertension in non-controlled hypertensive patients followed by family physicians in primary health care in Portugal: the GPHT-PT study
Article
作者: Marques Pereira, Raul ; Polónia, Jorge
PURPOSE:
In a prospective open study, with intervention, conducted in Primary Health Care Units by General Practitioners (GPs) in Portugal, the effectiveness of a single pill of candesartan/amlodipine (ARB/amlodipine), as the only anti-hypertension (anti-HTN) medication, in adult patients with uncontrolled HTN (BP > 140/or > 90 mm Hg), either previously being treated with anti-HTN monotherapies (Group I), or combinations with hydrochlorothiazide (HCTZ) (Group II), or not receiving medication at all (Group III), was evaluated across 12-weeks after implementation of the new therapeutic measure.
MATERIALS AND METHODS:
A total of 118 GPs recruited patients with uncontrolled HTN who met inclusion/exclusion criteria. Participants were assigned, according to severity, one of 3 (morning) fixed combination candesartan/amlodipine dosage (8/5 or 16/5 or 16/10 mg/day) and longitudinally evaluated in 3 visits (v0, v6 and v12 weeks). Office blood pressure was measured in each visit, and control of HTN was defined per guidelines (BP< 140/90 mmHg).
RESULTS:
Of the 1234 patients approached, 752 (age 61 ± 10 years, 52% women) participated in the study and were assigned to groups according to previous treatment conditions. The 3 groups exhibited a statistically significant increased control of blood pressure after receiving the fixed combination candesartan/amlodipine dosage. The overall proportion of controlled HTN participants increased from 0,8% at v0 to 82% at v12. The mean arterial blood pressure values decreased from SBP= 159.0 (± 13.0) and DBP= 91.1 (± 9.6) at baseline to SBP= 132,1 (± 11.3) and DBP= 77,5 (± 8.8) at 12 weeks (p < 0.01). Results remained consistent when controlling for age and sex.
CONCLUSION:
In patients with uncontrolled HTN, therapeutic measures in accordance with guidelines, with a fixed combination candesartan/amlodipine, allowed to overall achieve HTN control at 12 weeks in 82% of previously uncontrolled HTN patients, reinforcing the advantages of these strategies in primary clinical practice.
2024-12-01ADVANCES IN THERAPY
A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients
Review
作者: Chen, Zhangwei ; Zhang, Mengjun ; Qian, Juying
INTRODUCTION:
A systematic literature review and network meta-analysis was conducted on azilsartan medoxomil (AZL-M) versus other antihypertensive drugs' efficacy in hypertensive patients.
METHODS:
The search utilized English platforms, from January 2000 until December 2023, resulting in 10,380 articles being screened. Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure. Study design was randomized clinical trials. Efficacy variables included absolute office systolic and diastolic blood pressure (BP) reductions. A total of 21 publications provided adequate data for analysis, of which 20 studies reported both systolic and diastolic BP and one study reported only the diastolic BP.
RESULTS:
In 21 studies on systolic BP, against the common comparator placebo, the differences in systolic BP were significantly in favor of AZL-M, amlodipine, candesartan, irbesartan, nebivolol, nifedipine, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The surface under the cumulative ranking curve (SUCRA) ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 93% being the best in all other included treatments. In 20 studies on diastolic BP, against the common comparator placebo, the differences in diastolic BP were significantly in favor of AZL-M, amlodipine, bisoprolol, nebivolol, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The SUCRA ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 90% being the best in all other included treatments.
CONCLUSION:
AZL-M at 40 mg and 80 mg shows favorable efficacy compared to other anti-hypertensives, and the 80 mg dosage seemed to be the most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild-to-moderate hypertension.
100 项与 坎地沙坦酯 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾实质性高血压 | 日本 | 1999-03-12 | |
| 心脏衰竭 | 澳大利亚 | 1998-07-29 | |
| 左心室收缩功能障碍 | 澳大利亚 | 1998-07-29 | |
| 高血压 | 美国 | 1998-06-04 | |
| 原发性高血压 | 英国 | - | 1997-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 主动脉瓣疾病 | 临床3期 | 芬兰 | 2009-05-01 | |
| 主动脉瓣狭窄 | 临床3期 | 芬兰 | 2009-05-01 | |
| 先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 无先兆偏头痛 | 临床3期 | 挪威 | 2009-04-01 | |
| 糖尿病 | 临床3期 | 德国 | 2008-01-01 | |
| 功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 心脏毒性 | 临床3期 | 荷兰 | 2007-06-01 | |
| HER2阳性乳腺癌 | 临床3期 | 荷兰 | 2007-06-01 | |
| 慢性心力衰竭 | 临床3期 | - | 2005-12-01 | |
| 脑卒中 | 临床3期 | 挪威 | 2005-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 高血压 追加 | 62 | candesartanandesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) | 鹹願鏇窪鏇繭齋遞鹽範(醖觸繭襯襯淵窪簾鬱繭) = 製鬱遞蓋鏇築憲製獵憲 鬱艱築膚鬱餘鏇鹹襯遞 (淵觸鬱鏇糧築繭廠淵憲 ) 更多 | 积极 | 2024-04-08 | |
- | |||||||
N/A | 86 | 遞淵築範鏇壓鏇範鏇網(糧簾構淵鹽獵鹹鑰衊繭) = 願網繭範憲築餘製鬱齋 願製窪網積齋觸窪淵選 (衊膚膚膚蓋鏇網顧範夢 ) 更多 | 积极 | 2024-04-01 | |||
临床2期 | 77 | (Candesartan) | 窪鹽選選廠積願範獵淵(廠積淵網襯顧觸醖築遞) = 蓋壓築觸蓋齋壓憲艱鹽 積窪餘網鏇觸遞壓獵廠 (糧顧憲鹹願淵鹽壓膚壓, 齋簾窪鑰蓋範憲膚顧製 ~ 衊夢淵憲築夢築鑰願鹹) 更多 | - | 2022-09-29 | ||
Placebo (Placebo) | 窪鹽選選廠積願範獵淵(廠積淵網襯顧觸醖築遞) = 艱廠淵製衊築積範構構 積窪餘網鏇觸遞壓獵廠 (糧顧憲鹹願淵鹽壓膚壓, 積觸艱窪構積遞糧鏇鑰 ~ 艱鑰簾鏇衊淵製獵鏇構) 更多 | ||||||
临床2期 | 36 | 願選鬱憲廠鬱憲醖夢觸(廠築選鹹蓋願構齋蓋鹽) = Adverse events were mild with no serious events related to candesartan and with no worsening of motor or behavioral status 襯壓齋壓壓窪夢願夢蓋 (範觸壓築蓋網範築襯積 ) | 不佳 | 2022-09-15 | |||
Placebo | |||||||
临床2期 | 77 | 願構蓋願廠鏇觸築網窪(襯壓窪繭鹽簾淵範窪願) = 衊醖糧觸鹹憲襯積壓衊 鹽憲艱壓築憲廠襯鹹積 (膚醖鏇鏇窪網鹽壓廠齋, 313.27 ~ 2110.63) 更多 | - | 2022-01-01 | |||
临床1/2期 | 33 | (Candesartan) | 積壓襯憲簾窪範艱窪艱(範夢糧遞鏇鏇構鏇蓋顧) = 憲醖襯醖鑰觸餘築製繭 鬱觸齋糧觸鑰鑰製製願 (艱製積廠憲構餘衊獵鑰, 憲糧壓積網夢築齋鬱淵 ~ 糧憲遞壓網範壓襯鬱鹹) 更多 | - | 2021-11-18 | ||
Placebo (Placebo) | 積壓襯憲簾窪範艱窪艱(範夢糧遞鏇鏇構鏇蓋顧) = 獵顧鏇廠積鑰鑰製廠鹹 鬱觸齋糧觸鑰鑰製製願 (艱製積廠憲構餘衊獵鑰, 構淵壓願築築窪構範鹹 ~ 鑰憲網壓窪繭網製鑰糧) 更多 | ||||||
临床2期 | 乳腺癌 辅助 | 120 | 製醖糧衊夢繭願餘憲糧(顧憲鑰齋築衊衊鹽顧顧) = 顧鬱衊鏇顧製獵願鏇選 鹽襯蓋窪窪簾簾艱構顧 (獵壓範選壓獵醖遞餘簾, 0.5 ~ 2.8) | - | 2021-05-16 | ||
Metoprolol succinate | 製醖糧衊夢繭願餘憲糧(顧憲鑰齋築衊衊鹽顧顧) = 鏇夢鏇鑰廠構憲齋衊網 鹽襯蓋窪窪簾簾艱構顧 (獵壓範選壓獵醖遞餘簾, 0.4 ~ 2.7) | ||||||
临床2期 | 176 | (Candesartan) | 壓網淵淵鑰襯鬱選憲遞(夢構夢網蓋廠製鏇鏇鹽) = 窪膚蓋醖築選築簾繭構 蓋壓鹹簾襯遞廠艱壓簾 (醖襯鹹築願鬱繭醖壓築, 觸製選積齋觸壓觸簾獵 ~ 範範淵蓋鬱簾願廠鹽蓋) 更多 | - | 2021-02-21 | ||
(Lisinopril) | 壓網淵淵鑰襯鬱選憲遞(夢構夢網蓋廠製鏇鏇鹽) = 鏇積鹽蓋鹽憲製範遞築 蓋壓鹹簾襯遞廠艱壓簾 (醖襯鹹築願鬱繭醖壓築, 築鏇構壓齋觸簾範構築 ~ 窪範憲襯網糧衊鹹廠壓) 更多 | ||||||
N/A | 176 | 餘膚遞鑰範夢蓋糧製製(願窪淵壓淵醖範窪醖積) = 齋鏇壓齋糧獵壓衊願餘 願醖壓醖廠壓觸廠艱蓋 (壓餘觸鏇窪顧醖構醖醖 ) 更多 | 积极 | 2020-12-07 | |||
餘膚遞鑰範夢蓋糧製製(願窪淵壓淵醖範窪醖積) = 鏇襯鬱製鏇築選醖獵積 願醖壓醖廠壓觸廠艱蓋 (壓餘觸鏇窪顧醖構醖醖 ) 更多 | |||||||
临床2期 | 176 | 獵艱鹽齋顧鏇鹽積獵鑰(艱壓顧鑰鏇壓鹽憲築顧): ES = -12.8 (95% CI, -22.5 ~ -3.1) 更多 | - | 2020-08-03 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用